BMY Files Mezigdomide in Multiple Myeloma, Pipeline Progress Remains Distant

What happened

Bristol Myers Squibb submitted an FDA filing for mezigdomide in relapsed/refractory multiple myeloma, advancing its protein degrader pipeline. While this adds to the company's oncology story, mezigdomide is one of several late-stage pipeline assets whose revenue contribution is years away. Near-term performance hinges on Eliquis growth and gross margin stability in 2026, not pipeline filings. The mezigdomide filing is a positive signal for the long-term portfolio, but it does not alter the bridge-year economics that drive the current investment thesis.

Implication

The mezigdomide filing supports BMY's protein degrader strategy, but investors should not overweigh it near-term. The stock's valuation depends on evidence that Eliquis can deliver 10-15% growth in 2026 while gross margin holds at 69-70%. Until Q2 2026 results confirm margin stability, the risk-reward remains unattractive. Pipeline successes are already partially priced in as optionality; execution on the bridge year is what moves the stock.

Thesis delta

The mezigdomide filing is a mild positive for BMY's pipeline credibility, but it does not shift the near-term thesis. The master report's WAIT rating remains intact; the key catalysts are Q1 and Q2 2026 financials, not regulatory submissions. The delta is that the CELMoD program adds to the growth portfolio narrative but does not change the timeline for bridge-year validation.